ヒトの微生物群は,全身性自己免疫性関節疾患の免疫抑制療法と相互作用するのでしょうか. 体系的なレビュー
Noemí Franco-Domingo1, Patricia Saiz-López2, Loreto Carmona-Ortells3
1Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain.
Reumatologia clinica
|August 29, 2025
まとめ
ヒトの微生物群 (HM) と自己免疫疾患 (ARD) の免疫抑制薬 (IS) についての研究は,潜在的な関連を示しています. 腸内微生物群の変化は治療への反応に影響を与えるかもしれないが,より標準化された研究が必要である.
科学分野:
- 免疫学と微生物学
- リウマトロジ
- 胃腸内科
背景:
- システム性自己免疫性関節疾患 (ARD) は,免疫系と外部要因の複雑な相互作用を伴う.
- 免疫抑制薬 (IS) の治療は,ARDの管理に不可欠ですが,その有効性は患者によって大きく異なります.
- 人間の微生物群 (HM),特に腸内微生物群は,免疫系調節における役割としてますます認識されています.
研究 の 目的:
- 組織的自己免疫性関節疾患の患者におけるヒトの微生物群と免疫抑制薬の相互作用に関する既存の研究を体系的にレビューし,分析する.
- これらの相互作用が病気の活動と治療への反応に与える影響を評価する.
- 現在の研究におけるギャップを特定し,将来の研究のための方向性を提案する.
主な方法:
- 電子データベース (Medline,Embase,Cochrane Library) を使って2024年2月まで体系的なレビューが行われました.
- HMとIS治療の相互作用を調査し,多様性と分類組成を測定したARD (脊椎関節炎を除く) の成人の患者に焦点を当てた研究が含まれています.
- どの言語でも研究が検討され,臨床試験を優先し,観察と症例対照の設計を含めた.
主要な成果:
- 20件の研究 (15件は関節リウマチ,3件は全身性赤血性狼,1件は小児性シェーグレン症候群,1件は全身性硬化症) が含まれており,全体的にバイアスのリスクは中等であった.
- 研究は,研究不足と特異性のために主に腸内微生物群に限られていた.
- IS治療に反応した患者の部分的な回復とともに,腸内微生物多様性の減少と組成の変化を示した.
結論:
- 現在の証拠は,ヒトの微生物群と,自己免疫性関節疾患における免疫抑制療法への反応との間の潜在的な関連を示唆している.
- 適度な証拠の質と方法論的な異質性は,決定的な結論を制限する.
- 微生物群の研究方法の標準化は,データを統合し,より堅実な推論を導き出すために不可欠です.
関連する概念動画
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
Autoimmune Disorders
667
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
667
Inflammatory Bowel Disease IV: Pharmacological Management
185
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
185
T Cell Types and Functions
1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
230
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
230
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
201
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
201


